

CHEMBIO DIAGNOSTICS, INC.  
Form 8-K  
June 01, 2006

---

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF  
THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported) **May 30, 2006**

**CHEMBIO DIAGNOSTIC, INC.**

(Exact name of registrant as specified in its charter)

<b>Nevada</b>	<b>0-30379</b>	<b>88-0425691</b>
(State or other	(Commission	(IRS
jurisdiction	File Number)	Employer
of		Identification
Incorporation)		Number)

**3661  
Horseblock  
Road  
Medford, NY  
11763**

(Address of  
principal  
executive  
offices)

**631-924-1135**  
(Registrant's  
Telephone  
Number)

**N/A**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
- 

**ITEM 7.01. Regulation FD Disclosures.**

- (a) On May 30, 2006 the Registrant issued the press release titled “Chembio Receives FDA Approval for its Rapid HIV Tests” included herein as Exhibit 99.1.
- (b) On May 31, 2006 the Registrant issued the press release titled “Chembio to Participate in the United Nations High Level Meetings on Aids” included herein as Exhibit 99.2.

**ITEM 9.01. Financial Statements and Exhibits**

- (c) Exhibits.

99.1 Press Release titled “Chembio Receives FDA Approval for its Rapid HIV Tests” issued May 30, 2006.  
99.2 Press Release titled “Chembio to Participate in the United Nations High Level Meetings on Aids” issued May 31, 2006.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: May 31, 2006 Chembio Diagnostics, Inc.

By: /s/ Lawrence A. Siebert  
Lawrence A. Siebert  
Chief Executive Office